Progyny (PGNY) Financials

Progyny’s Q1 2026 results show a business that is still growing, still profitable, and still generating solid operating cash flow, but it is also increasingly using cash for share repurchases and carries a fairly leveraged balance sheet compared with its cash position.

Revenue in Q1 2026 rose to $328.5 million from $318.4 million in Q4 2025 and $324.0 million in Q1 2025. Net income came in at $24.2 million, up from $12.5 million in the prior quarter and $15.1 million a year ago. On the cash flow side, Progyny generated $45.9 million in operating cash flow in the quarter, which remains a healthy sign for a company in this space.

That said, the quarter also showed some pressure in profitability mix. Gross margin was roughly 25.3% in Q1 2026, down from about 26.1% in Q4 2025 and well below the 27.6%-29.0% range seen in early 2025 and 2024. Revenue is growing, but cost of revenue is rising too, which is limiting margin expansion.

Here are the most important trends investors should know:

• Revenue has continued to expand year over year, with Q1 2026 sales up from Q1 2025 and Q1 2024 levels.
• Operating cash flow remains strong at $45.9 million in Q1 2026, supporting the core business.
• The company remains solidly profitable, with $24.2 million in net income in Q1 2026.
• Progyny still has meaningful liquidity, including $131.6 million in cash and equivalents and $93.5 million in short-term investments at quarter-end.
• Retained earnings have continued to build over time, reflecting cumulative profitability.
• Q1 2026 diluted EPS was $0.29, up from $0.14 in Q4 2025, but EPS can be influenced by share count changes and quarterly timing.
• The company generated a large amount of cash from investment maturities/sales in Q1 2026, which boosted investing cash flow.
• Accounts receivable remain substantial at $263.6 million, which is normal for the business but worth monitoring for collection trends.
• Goodwill and intangible assets are relatively modest versus total assets, so the balance sheet is not overly dependent on acquisition-related assets.
• Margins have softened over the last year, with gross profit dollars growing slower than revenue and cost of revenue taking a larger share of sales.
• The company spent $118.6 million on common equity repurchases in Q1 2026, which is a large use of cash.
• Total liabilities of $259.0 million are sizable relative to cash on hand, so balance sheet flexibility is not unlimited.
• Accounts payable and accrued expenses remain significant current liabilities, which adds pressure to working capital management.

Looking at the multi-year pattern, Progyny has generally been able to grow revenue and stay profitable, but profitability has been uneven quarter to quarter. In 2023 and 2024, revenue trended upward and operating income remained positive, while operating cash flow was consistently strong. The standout change in 2025 and into Q1 2026 is not a collapse in the business, but a shift toward slightly weaker margin performance and heavier capital return activity.

Bottom line: Progyny still looks like a financially healthy, cash-generative business, but investors should watch for whether revenue growth can reaccelerate margins and whether aggressive share repurchases continue to consume a large portion of operating cash.